CIK 0001714899
DNLI Denali Therapeutics Inc.
Insider trading from SEC Form 4. Last filing Dec 31, 2024.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
5
with a Form 4 at this company
Signals
Open-market buys and sells at Denali Therapeutics Inc., scored.
| Score | Side | Insider | Value | Shares | Holdings change | Price context | Filed |
|---|---|---|---|---|---|---|---|
| 40Moderate | sell 310b5-1 | Schenkein David P director | $1.9M | 59,441 | -87% | - | |
| 15Weak | sell 310b5-1 | SATO VICKI L director | $31k | 1,020 | -1% | - | |
| 12Weak | sell 310b5-1 | Schuth Alexander O. COFO and Secretary | $465k | 15,558 | -8% | - | |
| 19Weak | sell 410b5-1 | SATO VICKI L director | $83k | 3,080 | -3% | - | |
| 28Weak | sell 210b5-1 | Watts Ryan J. President and CEO | $1.1M | 40,000 | -15% | - |
Transactions
The last 20 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Dec 27, 2024 | Schuth Alexander O. COFO and Secretary | MOption exercise Common Stock | +6,708 | $5.28 | $35k | 205,290 | Dec 31, 2024 |
| Dec 27, 2024 | Schuth Alexander O. COFO and Secretary | MOption exercise Stock Option (right to buy)derivative | -6,708 | $0.00 | $0 | 46,671 | Dec 31, 2024 |
| Nov 25, 2024 | Ho Carole Chief Medical Officer | MOption exercise Common Stock | +17,845 | $0.68 | $12k | 136,655 | Nov 27, 2024 |
| Nov 25, 2024 | Ho Carole Chief Medical Officer | MOption exercise Stock Option (right to buy)derivative | -17,845 | $0.00 | $0 | 107,155 | Nov 27, 2024 |
| Nov 22, 2024 | Schuth Alexander O. COFO and Secretary | MOption exercise Common Stock | +20,516 | $0.68 | $14k | 198,582 | Nov 26, 2024 |
| Nov 22, 2024 | Schuth Alexander O. COFO and Secretary | MOption exercise Stock Option (right to buy)derivative | -20,516 | $0.00 | $0 | 124,562 | Nov 26, 2024 |
| Nov 11, 2024 | Schenkein David P director | MOption exercise Common Stock10b5-1 | +47,165 | $18.00 | $849k | 68,661 | Nov 13, 2024 |
| Nov 11, 2024 | Schenkein David P director | SOpen-market sale Common Stock10b5-1 | -27,129 | $32.09 | $871k | 41,532 | Nov 13, 2024 |
| Nov 11, 2024 | Schenkein David P director | SOpen-market sale Common Stock10b5-1 | -32,312 | $32.87 | $1.1M | 9,220 | Nov 13, 2024 |
| Nov 11, 2024 | Schenkein David P director | MOption exercise Stock Option (right to buy)derivative10b5-1 | -47,165 | $0.00 | $0 | 0 | Nov 13, 2024 |
| Nov 7, 2024 | SATO VICKI L director | SOpen-market sale Common Stock10b5-1 | -1,020 | $30.00 | $31k | 111,056 | Nov 12, 2024 |
| Nov 7, 2024 | Schuth Alexander O. COFO and Secretary | MOption exercise Common Stock10b5-1 | +15,558 | $5.28 | $82k | 193,624 | Nov 12, 2024 |
| Nov 7, 2024 | Schuth Alexander O. COFO and Secretary | SOpen-market sale Common Stock10b5-1 | -12,333 | $29.68 | $366k | 181,291 | Nov 12, 2024 |
| Nov 7, 2024 | Schuth Alexander O. COFO and Secretary | SOpen-market sale Common Stock10b5-1 | -2,925 | $30.72 | $90k | 178,366 | Nov 12, 2024 |
| Nov 7, 2024 | Schuth Alexander O. COFO and Secretary | SOpen-market sale Common Stock10b5-1 | -300 | $31.29 | $9,387 | 178,066 | Nov 12, 2024 |
| Nov 7, 2024 | Schuth Alexander O. COFO and Secretary | MOption exercise Stock Option (right to buy)derivative10b5-1 | -15,558 | $0.00 | $0 | 53,379 | Nov 12, 2024 |
| Nov 1, 2024 | SATO VICKI L director | SOpen-market sale Common Stock10b5-1 | -3,080 | $27.07 | $83k | 112,076 | Nov 5, 2024 |
| Oct 18, 2024 | Watts Ryan J. President and CEO | MOption exercise Common Stock10b5-1 | +40,000 | $0.68 | $27k | 275,807 | Oct 22, 2024 |
| Oct 18, 2024 | Watts Ryan J. President and CEO | SOpen-market sale Common Stock10b5-1 | -40,000 | $27.69 | $1.1M | 235,807 | Oct 22, 2024 |
| Oct 18, 2024 | Watts Ryan J. President and CEO | MOption exercise Stock Option (right to buy)derivative10b5-1 | -40,000 | $0.00 | $0 | 1,078,091 | Oct 22, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Ho CaroleChief Medical Officer
- SATO VICKI Ldirector
- Schenkein David Pdirector
- Schuth Alexander O.COFO and Secretary
- Watts Ryan J.President and CEO
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.